Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.

[1]  Angelo Branzi,et al.  Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. , 2007, European heart journal.

[2]  William Wijns,et al.  [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[3]  J. Ornato,et al.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie , 2007, Journal of the American College of Cardiology.

[4]  M. Sabatine,et al.  Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28 , 2007, Journal of Thrombosis and Thrombolysis.

[5]  F. Neumann,et al.  Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. , 2006, Journal of the American College of Cardiology.

[6]  K. Alexander,et al.  Sex Differences in Major Bleeding With Glycoprotein IIb/IIIa Inhibitors: Results From the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines) Initiative , 2006, Circulation.

[7]  W. Gibler,et al.  Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST-segment elevation acute coronary syndromes. , 2006, The American journal of cardiology.

[8]  A. Kastrati,et al.  Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. , 2006, JAMA.

[9]  S. Steinhubl,et al.  Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. , 2006, Journal of the American College of Cardiology.

[10]  Lippincott Williams Wilkins,et al.  ACC/AHA/SCAI Practice Guidelines, February 21, 2006 , 2006 .

[11]  J. Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.

[12]  S. Yusuf,et al.  Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. , 2005, American heart journal.

[13]  A. Kastrati,et al.  Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial , 2005, Circulation.

[14]  B. Lewis,et al.  Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. , 2005, JAMA.

[15]  Antonio Colombo,et al.  Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. , 2005, European heart journal.

[16]  A. Skene,et al.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. , 2005, The New England journal of medicine.

[17]  A. Kastrati,et al.  Loading With 600 mg Clopidogrel in Patients With Coronary Artery Disease With and Without Chronic Clopidogrel Therapy , 2004, Circulation.

[18]  S. Yusuf,et al.  Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial , 2004, Circulation.

[19]  P. Théroux,et al.  Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. , 2004, Journal of the American College of Cardiology.

[20]  C. Macaya,et al.  Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study. , 2004, The Journal of invasive cardiology.

[21]  Deepak L. Bhatt,et al.  Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. , 2004, The American journal of cardiology.

[22]  E. Vicaut,et al.  Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. , 2004, Journal of the American College of Cardiology.

[23]  Kevin P. Bliden,et al.  Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.

[24]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[25]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[26]  A. Weyrich,et al.  Platelets, endothelial cells, inflammatory chemokines, and restenosis: complex signaling in the vascular play book. , 2002, Circulation.

[27]  C. O'connor,et al.  Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. , 2002, The American journal of cardiology.

[28]  S. Harder,et al.  Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P‐selectin expression in a human ex vivo in vitro model , 2002, Clinical pharmacology and therapeutics.

[29]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.

[30]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[31]  M. Morice,et al.  Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. , 2001, The New England journal of medicine.

[32]  M. Seyfarth,et al.  Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement , 2001, Heart.

[33]  S. Pocock,et al.  A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .

[34]  B. Nowak,et al.  Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. , 1998, Circulation.

[35]  P. Teirstein,et al.  Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.